Trimeris, Inc., biopharmaceutical company focusing on viral disease treatment

Oct. 2, 2009 - Trimeris, Inc. (NASDAQ:TRMS) today announced that it has entered into a merger agreement with Arigene Co., Ltd.

FUZEON^® is the first in a class of anti-HIV drugs called fusion inhibitors. Learn more about the only FDA-approved fusion inhibitor...